Gsa Capital Partners LLP Eye Point Pharmaceuticals, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 32,979 shares of EYPT stock, worth $284,278. This represents 0.02% of its overall portfolio holdings.
Number of Shares
32,979
Previous 14,363
129.61%
Holding current value
$284,278
Previous $125,000
111.2%
% of portfolio
0.02%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding EYPT
# of Institutions
153Shares Held
58.2MCall Options Held
177KPut Options Held
263K-
Cormorant Asset Management, LP Boston, MA8.33MShares$71.8 Million4.66% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.18MShares$44.6 Million1.63% of portfolio
-
Franklin Resources Inc San Mateo, CA4.01MShares$34.6 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.79MShares$32.7 Million0.06% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$32.5 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $294M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...